CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 143 enrolled
Drug / intervention
pneumococcal 23v polysaccharide vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00560950
NCT00560950Phase 3Completed
CompareCT.gov

A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults

Merck Sharp & Dohme LLC·interventional·Posted Nov 20, 2007·Updated Apr 11, 2017

In Brief

A Phase 3 clinical trial evaluating pneumococcal 23v polysaccharide vaccine for Pneumococcal Infection. Completed, enrolled 143 participants.

Detailed Summary

The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infection
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 20, 2007
Enrollment StartJul 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.6 years ago

Interventions

pneumococcal 23v polysaccharide vaccinebiological

Duration of Treatment: Single vaccination on Day 1